Drug Profile
Vistusertib - AstraZeneca
Alternative Names: AZD 2014Latest Information Update: 15 Dec 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; Cambridge University Hospitals; Massachusetts General Hospital; National Cancer Institute (USA); Netherlands Cancer Institute; NHS Greater Glasgow and Clyde; Queen Mary University of London; Samsung Medical Center; University of Birmingham; University of London; University of Texas M. D. Anderson Cancer Center
- Class 2 ring heterocyclic compounds; Antineoplastics; Benzamides; Cytostatics; Morpholines; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Diffuse large B cell lymphoma; Fallopian tube cancer; Gastric cancer; Glioblastoma; Meningioma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Renal cancer; Small cell lung cancer; Solid tumours
Most Recent Events
- 23 Nov 2023 AstraZeneca completes a phase I/II trial in Breast cancer (Late-stage disease, Combination therapy, Second-line therapy or greater) in the US and united kingdom (NCT02599714)
- 12 Jul 2021 Efficacy and adverse events data from a phase II/III trial in Meningioma presented at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)
- 04 Jun 2021 Adverse events and efficacy data from a phase I/II in endometrial cancer trial was presented at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)